Search results (7)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
How Oxford has shaped cancer science
4 February 2022
As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.
Medical imaging 'flight simulator' spun out as new company & training tool
3 December 2021
Radiologists at Oxford University Hospitals (OUH) NHS Foundation Trust & University of Oxford have set up a new company aimed at helping to improve the interpretation of medical imaging by clinicians, for many conditions including cancer.
Two Oxford immunotherapy research projects awarded funding by Prostate Cancer UK
31 August 2021
Prostate Cancer UK have invested £1.7 million into five immunotherapy projects, including two from Profs Kate Vallis, Richard Bryant and Eileen Parkes at the University of Oxford. Read about their funded work.
Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens
2 July 2021
University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.
Novel imaging device enters first round of development funding programme
29 March 2021
Anna Vella is designing CAPULET: a device to increase the accuracy in delivering particle beam radiotherapy in cancer treatment
Using big data in breast cancer research
22 October 2020
The Cancer Epidemiology Unit has been using the largest epidemiological data set of its kind to unlock the secrets of breast cancer, what can be done to prevent it, and which women are most likely to develop it
A new FRONTIER for breast cancer
13 October 2020
Latest news from FRONTIER, the trial investigating the potential of the radiotracer Fluciclovine in the subtyping and staging of breast cancers